FMP
MannKind Corporation
MNKD
NASDAQ
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
6.85 USD
0.55 (8.03%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Michael E. Castagna Pharm.D.
sector
Healthcare
industry
Biotechnology
website
https://www.mannkindcorp.comexchange
NASDAQ
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect ...
CIK
0000899460
ISIN
US56400P7069
CUSIP
56400P706
Address
30930 Russell Ranch Road
Phone
818 661 5000
Country
US
Employee
411
IPO Date
Jul 28, 2004
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
MNKD Financial Summary
CIK
0000899460
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
56400P706
ISIN
US56400P7069
Country
US
Price
6.85
Beta
1.3
Volume Avg.
2.51M
Market Cap
1.89B
Shares
-
52-Week
3.17-7.63
DCF
4.8
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
85.63
P/B
-
Website
https://www.mannkindcorp.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest MNKD News
It looks like there's no news available.
